Exai Bio Secures $67.5 Million Series A Financing to Advance Next-Generation, RNA-Based Liquid Biopsy Platform for Early Cancer Detection

VIEW ARTICLE
If you would like to know more regarding the topic in this blog post, please do not hesitate to contact us.